Nocendra Inc. Lipoxin Synthesis Patent Application, Apr 23
Summary
Nocendra Inc. filed patent application US20260108486A1 on December 17, 2025, covering methods of synthesizing lipoxin analogs (e.g., lipoxin mimetics) and pharmaceutical compositions comprising these pro-resolving compounds. The application lists Thomas E. Van Dyke and Charles N. Serhan as inventors. The published application includes CPC classifications A61K 31/202 and A61P 1/02.
“This disclosure relates to methods of synthesizing certain lipoxin analogs (e.g., lipoxin mimetics, etc.) and pharmaceutical compositions comprising these pro-resolving compounds.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
Nocendra Inc. filed patent application US20260108486A1 on December 17, 2025, for methods of synthesizing lipoxin analogs and pharmaceutical compositions comprising these pro-resolving compounds. The application covers lipoxin mimetics, including lipoxin A4 and lipoxin B4 mimetics, and methods of administering these compounds to patients in need thereof.
Affected parties include pharmaceutical companies and research institutions developing pro-resolving inflammatory therapies. While the application does not impose immediate compliance obligations, it establishes intellectual property claims that may affect freedom-to-operate assessments for competing therapeutic developers working in the lipoxin or specialized pro-resolving mediator space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR
Application US20260108486A1 Kind: A1 Apr 23, 2026
Assignee
Nocendra Inc.
Inventors
Thomas E. Van Dyke, Charles N. Serhan
Abstract
This disclosure relates to methods of synthesizing certain lipoxin analogs (e.g., lipoxin mimetics, etc.) and pharmaceutical compositions comprising these pro-resolving compounds. Methods of administering the lipoxin mimetics (e.g., lipoxin A4 mimetics, lipoxin B4 mimetics, etc.) to patients in need thereof are also provided.
CPC Classifications
A61K 31/202 A61P 1/02
Filing Date
2025-12-17
Application No.
19423860
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.